News monitoring that answers a question, not fills an inbox

How CHMP handles conditional marketing authorisations (CMAs) and the specific obligations it imposes

Methodology

This memo draws on three EU sources. The legal framework was taken from EudraLex (Commission Regulation (EC) No 507/2006 and its enabling provision, Article 14(7) of Regulation (EC) No 726/2004) ^54555152. CHMP's operational practice was taken from EMA scientific guidance on the procedural aspects of CMA and the handling of specific obligations (SOBs) ^67697290. Concrete examples of imposed obligations were pulled from EMA European Public Assessment Reports (EPARs); the products surfaced (Ocaliva, Lorviqua, Sirturo, Zalmoxis, Translarna, Caprelsa) are those whose Annex II obligations appeared in the matched pages ^1247811. Scope is the EU centralised procedure only; SOBs quoted are as recorded in each product's EPAR and may have been updated at later annual reassessments.

The legal framework CHMP applies

A CMA is an authorisation granted subject to specific obligations, on the basis of a data package that is less complete than normal, where the benefit of immediate availability outweighs the risk of residual uncertainty. It is set out in Commission Regulation (EC) No 507/2006, adopted under Article 14(7) of Regulation (EC) No 726/2004 ⁵⁴⁵⁵.

Eligibility (Article 2 of Reg 507/2006): the product must fall into one of three categories — treatment/prevention/diagnosis of seriously debilitating or life-threatening diseases; use in emergency situations in response to public-health threats; or an orphan-designated medicine ⁵⁴.

Grant conditions (Article 4(1)): even though comprehensive clinical data are missing, all of the following must hold — the benefit-risk balance is positive; it is likely the applicant will be able to provide the comprehensive data; unmet medical needs will be met; and the public-health benefit of immediate availability outweighs the risk from the still-missing data ⁵¹.

Specific obligations (SOBs) CHMP imposes

Article 5 of Reg 507/2006 is the core mechanism:

• The holder must complete ongoing studies, or conduct new studies, to confirm the benefit-risk balance and supply the additional data referred to in Article 4(1) ⁵¹⁵⁵.
• SOBs may also cover the collection of pharmacovigilance data ⁵¹.
• The obligations and their timeframe must be clearly specified in the authorisation and made publicly available by the Agency ⁵¹.

In CHMP practice, SOBs are binding conditions written into Annex II of the opinion/decision, and they are the anchor for the annual renewal cycle ⁹⁰. An SOB is typically an identified programme of studies to be completed within a set time; registries and observational cohort studies (reported annually on an agreed protocol) are given as examples, and SOBs can also be additional pharmacovigilance activities captured in the RMP ⁹⁰.

How CHMP manages SOBs over the CMA life cycle

Annual renewal (Article 6): the CMA is valid for one year and renewable annually ⁵¹. The renewal application is due at least six months before expiry with an interim report on fulfilment of each SOB ⁵¹. CHMP assesses whether the benefit-risk balance is confirmed in light of the SOBs and their timeframes, with a 90-day opinion window ⁵¹.

Handling interim vs final SOB data: interim results that do not change the product information or the SOB description can be submitted as a post-authorisation measure (PAM); interim results that do affect the product information should trigger a variation without waiting; final results fulfilling an SOB are submitted through the appropriate procedure — annual reassessment, annual renewal, or variation ⁷². At each annual reassessment CHMP reviews whether SOBs remain unchanged, whether data require MA changes, or whether benefit-risk has shifted enough to justify suspension or revocation ⁶⁷.

Conversion to a standard MA (Article 7): once the Article 5(1) obligations are fulfilled and comprehensive efficacy/safety data are available, CHMP may recommend a marketing authorisation no longer subject to SOBs, valid for five years; a CMA is not meant to remain conditional indefinitely ⁵¹⁵⁵. This distinct pathway should not be confused with authorisation "under exceptional circumstances" (Article 14(8) of Reg 726/2004), where comprehensive data are never expected ⁵².

Worked examples of imposed obligations (from EPARs)

These illustrate the recurring pattern: the headline SOB is a confirmatory or descriptive clinical study tied to the specific residual uncertainty (population subset, comparator, or long-term endpoint), with a named study code and a hard submission date, supplemented where relevant by annual progress reporting and pharmacovigilance measures.